Ontology highlight
ABSTRACT: Introduction
AXL receptor expression is proposed to confer immune-checkpoint inhibitor (ICI)-resistance in non-small cell lung cancer (NSCLC) patients. We sought to interrogate AXL expression in conjunction with mutational and tumor-microenvironmental features to uncover predictive mechanisms of resistance in ICI-treated NSCLC patients.Methods
Tumor samples from 111 NSCLC patients treated with ICI-monotherapy were analyzed by immunohistochemistry for tumor- and immune-AXL expression. Subsets of patients were analyzed by whole-exome sequencing (n = 44) and imaging mass cytometry (n = 14). Results were related to ICI-outcome measurements.Results
Tumor-cell AXL expression correlated with aggressive phenotypic features including reduced OS in patients treated with ICIs
SUBMITTER: Rayford A
PROVIDER: S-EPMC11375292 | biostudies-literature | 2024
REPOSITORIES: biostudies-literature